Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

Mizuho analyst Uy Ear has maintained an Outperform rating on Relmada Therapeutics (NASDAQ: RLMD) and increased the price target from $10 to $19. This adjustment reflects a positive outlook on the company's performance.